Clinical Study on Endometrial Receptivity

Endometrial Receptivity;RNA; Progesterone Clinical Trial

Official title:

Clinical Study on the Impact of Route of Administration of Progesterone and Endometriosis on Endometrial Receptivity

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03687021
• Other study ID #: yuqi03029
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: October 10, 2018
• Est. completion date: November 10, 2018

Study information

• Verified date: August 2018
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

to explore the differential expression of miRNA in the implantation window of patients with endometriosis and the time of progesterone and route of administration on planting window

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 35
• Est. completion date: November 10, 2018
• Est. primary completion date: October 10, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. The endometriosis group treatment group: Previous laparoscopy or laparotomy confirmed endometriosis;Regular menstruation, no rule vaginal bleeding;Ovarian reserve function is normal.

control group: Laparoscopic bilateral salpingectomy was performed due to ectopic pregnancy, benign ovarian changes and other reasons, with the exception of endometriosis during the operation.Regular menstruation, no rule vaginal bleeding;Ovarian reserve function is normal

2. progesterone group Women with hypothalamic amenorrhea or premature ovarian failure;Ages 18-40

Exclusion Criteria:

Patients with medical complications

Related Conditions & MeSH terms

• Endometrial Receptivity;RNA; Progesterone

Intervention

Drug:
• Progesterone
Different routes of administration of progesterone; Whether there is endometriosis

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	endometrial receptivity measured by pathology	35 samples will be measured.	3 months
Secondary	endometrial receptivity measured by immunohisochemistry	35 samples will be measured	3 months
Secondary	endometrial receptivity measured by Ribose Nucleic Acid (RNA)	35 samples will be measured	3 months
Secondary	endometrial receptivity measured by scanning electron microscope	35 samples will be measured	3 months